Endovascular News
-
Emerging Trends in the BioPharma Industry that you Need to Know
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. As a leader in the sector, it’s important to be aware of these developments to make informed decisions about your organization’s direction. In this blog post, we’ll explore some of the most significant emerging trends in ...
By Brio Group
-
Silk Road Medical Strengthens Leadership Team
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s ...
-
Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). The data was presented during a Late-Breaking Clinical Trial session at the 2022 ...
-
Puzzle Medical Devices Inc. Wins TCT 2022 Shark Tank Innovation Competition
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in ...
-
Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System
GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space HINGHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announces the commencement of its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a world-class MedTech research laboratory. The study is being conducted by top Key Opinion Leaders (KOLs). ...
-
Microbot Medical Strengthen its Scientific Advisory Board with the Recent Addition of Dr. Sebastian Flacke
HINGHAM, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a reputation within the interventional radiology community for its LIBERTY® Robotic System, today announced the newest appointment to its Scientific Advisory Board (SAB), Sebastian Flacke, M.D. The addition of this thought leader adds a key robotic pioneer, who has a history of ...
-
Microbot Medical Confirms GLP Pre-Clinical Trial is on Track to Commence Later this Month
HINGHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a market-leading research laboratory to conduct the Company’s GLP pre-clinical trial. The comprehensive trial, ...
-
Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced three new data sets will be presented during Late-Breaking Clinical Trial sessions at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) and the 2022 VEINS (Venous Endovascular ...
-
Confluent Medical Technologies Announces Grand Opening of Costa Rica Expansion
Confluent Medical Technologies (Confluent), today announced the Grand Opening of the latest addition to their large scale manufacturing center of excellence in Alajuela, Costa Rica expanding their capacity for Nitinol processing and catheter manufacturing. This new facility will be co-located with the existing Confluent Costa Rica facility and will add an additional 66,000 square feet to this ...
-
Synchron Announces First Human U.S. Brain-Computer Interface Implant
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in the U.S. using an endovascular BCI approach, which does not require invasive open-brain surgery. The procedure was performed at Mount Sinai West in ...
-
Synchron Appoints Kurt Haggstrom as Chief Commercial Officer
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. “I am honored and excited to join the Synchron team and be part of ...
-
FDA Grants Saranas DeNovo Designation for the Early Bird® Bleed Monitoring System
Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been granted de novo classification by the U.S. Food and Drug Administration (FDA) for the Early Bird Bleed Monitoring System. According to a recent study of over 17,000 large-bore transcatheter interventions ...
-
Saranas Recognized as One of Houston’s Most Innovative Companies
Saranas Inc., a medical device company pioneering technology for real-time detection and monitoring of internal bleeding during endovascular procedures, today announced that it has been named one of Houston’s most innovative companies. Saranas is the only medical device company to be honored at the inaugural Innovation Awards presentation sponsored by the Houston Business Journal on ...
-
Saranas™ Announces Initial Clinical Cases with the Early Bird™ Bleed Monitoring System
Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, announced that the first clinical cases with Early Bird Bleed Monitoring System were performed at Atlantic Health System’s Morristown Medical Center (Morristown, NJ). The cases varied across multiple interventions including ...
-
Saranas Launches Early Bird® Bleed Monitoring System in the U.S.
Saranas, Inc. today announced the commercial launch of the Early Bird Bleed Monitoring System in the United States. The Early Bird is the first and only device for the monitoring and early detection of endovascular bleed complications through a novel application of bioimpedance sensors. Saranas will demonstrate the device in Booth 1755 at the Transcatheter Cardiovascular Therapeutics (TCT) ...
-
Saranas Awarded Technology Breakthroughs Contract with Premier
Saranas, Inc., developer of the Early Bird® Bleed Monitoring System designed for early detection of internal bleed complications during endovascular procedures, has been awarded a group purchasing agreement with Premier Inc., as part of Premier’s Technology Breakthroughs program. This new agreement, effective November 1, 2020, will allow Premier’s network of over 4,100 U.S. ...
-
Saranas Announces Peer-Reviewed Publications Highlighting Accuracy And Clinical Utility Of Early Bird Bleed Monitoring System
Saranas, Inc., developer of the Early Bird® Bleed Monitoring System for the monitoring and early detection of internal bleed complications during endovascular procedures, announced the online publication of two peer-reviewed articles highlighting the system’s accuracy and performance. The publications provide evidence of the Early Bird’s reliability to detect the early onset and ...
-
SANUWAVE Health and JV Partner Diversa S.A. Announce Distribution Agreement with Grupo Suprimed
SANUWAVE Health, Inc. (OTCQB:SNWV), a leading provider of next-generation wound care products and its JV partner Diversa S.A. have announced a new distribution agreement with Grupo Suprimed to market and sell the dermaPACE® System in the private healthcare market in Brazil. The dermaPACE® System is currently licensed or approved for advanced wound care indications in Brazil, Mexico and ...
-
Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous ...
-
Team Gleason Partners with Synchron to Redefine Accessibility
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you